Business
Cue Biopharma Announces CEO Transition
Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down\nBOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma’s chief financial and business officer since February 2026 and previously as Cue Biopharma’s chief business officer from September 2024 until February 2026, has been appointed interim president and chief executive officer (CEO). Usman Azam has stepped down as president and CEO and as a director, effective March 26, 2026. “The board of directors thanks Usman for his services to Cue,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “Furthermore, we are delighted that Lucinda has accepted to step into the president and CEO role during this transition period. Lucinda has successfully executed multiple valuable deals for the Company in the past year, including the return of worldwide development and commercialization rights for CUE-401, our collaboration with Boehringer Ingelheim for CUE-501, and our strategic collaboration and license agreement with ImmunoScape to develop a breakthrough cell therapy for solid tumors. The board is fully supportive and behind Lucinda in her new role, as Cue progresses CUE-401 toward the clinic, and as we continue to pursue creative deals to build value for our shareholders.” Ms. Warren, added, “I’m honored and committed to lead Cue Biopharma at this time, focused on continuing to drive our key priority of moving CUE-401 into the clinic by the second half of this year.” Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Her leadership was instrumental in optimizing resources, fostering high-performing teams, and cultivating strong relationships with stakeholder...